Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
Aminosyn II 4.25% in Dextrose 20% provides amino acids for protein synthesis and dextrose as a caloric source. Amino acids are utilized for tissue repair and maintenance, while dextrose provides energy via glycolysis and oxidative phosphorylation.
Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.
Intravenous infusion of 500 mL to 1 L per day. Typical rate: 1-2 mL/min (60-120 mL/hr). Adjust based on caloric and fluid requirements.
None Documented
None Documented
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
Not applicable; components are endogenous substances. Clinical effect (nitrogen balance) persists 4-6 hours post-infusion.
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Amino acids undergo metabolism; excess nitrogen is excreted renally as urea (80-90%), with minimal biliary/fecal elimination (<5%). Dextrose is metabolized.
Category C
Category C
Amino Acid Solution
Amino Acid Solution